Compare CELU & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CELU | XGN |
|---|---|---|
| Founded | 2016 | 2002 |
| Country | United States | United States |
| Employees | 123 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.2M | 71.2M |
| IPO Year | N/A | 2014 |
| Metric | CELU | XGN |
|---|---|---|
| Price | $0.97 | $5.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $6.00 | ★ $8.86 |
| AVG Volume (30 Days) | 118.7K | ★ 489.0K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $8.12 |
| Revenue Next Year | $76.00 | $13.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.71 | $2.59 |
| 52 Week High | $4.35 | $12.23 |
| Indicator | CELU | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 48.05 | 76.73 |
| Support Level | $0.71 | $2.68 |
| Resistance Level | $1.44 | $6.75 |
| Average True Range (ATR) | 0.07 | 0.43 |
| MACD | 0.02 | 0.15 |
| Stochastic Oscillator | 81.10 | 96.60 |
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.